Literature DB >> 1302046

Evidence for a dissociation in the control of sparteine, debrisoquine and metoprolol metabolism in Nigerians.

M S Lennard1, A O Iyun, P R Jackson, G T Tucker, H F Woods.   

Abstract

The 0-8 hour urinary distributions of the metabolic ratios of sparteine (100 mg), debrisoquine (10 mg) and metoprolol (100 mg) were measured in 165 healthy, unrelated, black Nigerian medical students. There was a weak correlation (rs = 0.51, p < 0.001; n = 82) between the metoprolol/alpha-hydroxymetoprolol (M/HM) and the sparteine/total (2- + 5-) dehydrosparteine (S/DHS) ratios. No significant correlations were found between the debrisoquine/4-hydroxydebrisoquine (D/HD) and M/HM ratios (rs = 0.16, n = 33) and between the D/HD and S/DHS ratios (rs = 0.31, n = 38). Both visual inspection and kernel density analysis of the data suggested the presence of two phenotypic groups for sparteine oxidation, with 4% of the population studied being putative poor metabolizers. In contrast biomodality was not apparent in the distribution of the log10M/HM and log10D/HD ratios. These findings provide evidence for a dissociation in the control of metoprolol, sparteine and debrisoquine oxidation in Nigerians and highlight the difficulties in the interpretation of data from pharmacogenetic studies in different ethnic groups.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1302046     DOI: 10.1097/00008571-199204000-00006

Source DB:  PubMed          Journal:  Pharmacogenetics        ISSN: 0960-314X


  9 in total

1.  Phenotypes and genotypes for CYP2D6 and CYP2C19 in a black Tanzanian population.

Authors:  L Bathum; E Skjelbo; T K Mutabingwa; H Madsen; M Hørder; K Brøsen
Journal:  Br J Clin Pharmacol       Date:  1999-09       Impact factor: 4.335

Review 2.  Evaluation of probe drugs and pharmacokinetic metrics for CYP2D6 phenotyping.

Authors:  D Frank; U Jaehde; U Fuhr
Journal:  Eur J Clin Pharmacol       Date:  2007-02-02       Impact factor: 2.953

Review 3.  Precision medicine: does ethnicity information complement genotype-based prescribing decisions?

Authors:  Rashmi R Shah; Andrea Gaedigk
Journal:  Ther Adv Drug Saf       Date:  2017-12-01

4.  Evaluation of CYP2D6 phenotype in the Yoruba Nigerian population.

Authors:  Waheed Adeola Adedeji; Sharon Iyobor Igbinoba; Titilayo O Fakeye; Ibrahim Adebayo Oladosu; Fatai Adewale Fehintola; Qing Ma; Gene D Morse
Journal:  Expert Rev Clin Pharmacol       Date:  2017-08-30       Impact factor: 5.045

5.  Identification and characterization of novel sequence variations in the cytochrome P4502D6 (CYP2D6) gene in African Americans.

Authors:  A Gaedigk; A Bhathena; L Ndjountché; R E Pearce; S M Abdel-Rahman; S W Alander; L DiAnne Bradford; P K Rogan; J Steven Leeder
Journal:  Pharmacogenomics J       Date:  2005       Impact factor: 3.550

6.  Dextromethorphan metabolism in Jordanians: dissociation of dextromethorphan O-demethylation from debrisoquine 4-hydroxylation.

Authors:  Y M Irshaid; H F al-Hadidi; A Latif; F Awwadi; M al-Zoubi; N M Rawashdeh
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1996 Oct-Dec       Impact factor: 2.441

7.  Metoprolol alpha-hydroxylation is a poor probe for debrizoquine oxidation (CYP2D6) polymorphism in Jordanians.

Authors:  H F al-Hadidi; Y M Irshaid; N M Rawashdeh
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

8.  The pharmacokinetics of codeine and its metabolites in Blacks with sickle cell disease.

Authors:  Stacy S Shord; Larisa H Cavallari; Weihua Gao; Hyun-Young Jeong; Kelly Deyo; Shitalben R Patel; Joseph R Camp; Susan M Labott; Robert E Molokie
Journal:  Eur J Clin Pharmacol       Date:  2009-04-09       Impact factor: 2.953

Review 9.  A new therapeutic option for postoperative pain management with oxycodone HCI injection.

Authors:  Byung Moon Choi
Journal:  Korean J Anesthesiol       Date:  2016-06-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.